share_log

Silence Therapeutics Seeks Approval to Cancel AIM Trading

Silence Therapeutics Seeks Approval to Cancel AIM Trading

沉默治疗公司寻求批准取消AIM交易
Dow Jones Newswires ·  2021/10/15 02:40

By Ian Walker

伊恩·沃克(Ian Walker)著

Silence Therapeutics PLC said Friday that it is seeking shareholder approval to cancel its listing on London's junior AIM, keeping a single listing on New York's Nasdaq.

沉默治疗公司周五表示,它正在寻求股东批准,取消其在伦敦初级AIM的上市,保留在纽约纳斯达克(Nasdaq)的单一上市。

The medical company said delisting from AIM will enhance liquidity in its American Depositary Shares and increase U.S. investors' willingness to invest in the company.

这家医疗公司表示,从AIM退市将增强其美国存托股票的流动性,并增加美国投资者投资该公司的意愿。

If approved by shareholders at a general meeting on Nov. 1, the last trading day on AIM is expected to be Nov. 29, it said.

该公司表示,如果在11月1日的股东大会上获得股东批准,AIM的最后一个交易日预计将是11月29日。

Write to Ian Walker at ian.walker@wsj.com

写信给Ian Walker:ian.walker@wsj.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发